# Dalbavancin (Dalvance)

> Long-acting lipoglycopeptide for skin and soft tissue infections.

Source: https://peptides.cafe/peptide/dalbavancin
Category: Lipoglycopeptide · Infectious Disease
Tag: FDA-Approved · Antibiotic

## Mechanism
Semi-synthetic lipoglycopeptide that binds D-Ala-D-Ala, inhibiting Gram-positive cell wall synthesis; long terminal half-life supports single- or two-dose courses.

## Research areas
- Acute bacterial skin and skin structure infections (ABSSSI)
- S. aureus bacteremia (investigational)

## Common research protocols
- ABSSSI: 1500 mg IV single dose, or 1000 mg then 500 mg one week later.

## Study summaries
- "DISCOVER 1 & 2 trials" — NEJM (2014): Non-inferior to vancomycin/linezolid for ABSSSI with simpler dosing.

## Considerations
- FDA-approved.
- Allows outpatient single-dose treatment.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.